chronic hand eczema
Dermatology · 2025–2025
1decision
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| delgocitinib Treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not… | Nov 2025 | Recommended with restriction | 2 individuals Eczema Support Australia · Eczema Association Australia |
Who spoke
Eczema Support Australia · Eczema Association Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| delgocitinibDelgocitinib for treating moderate to severe chronic hand eczema | TA1107 | recommended restricted | 2025-11 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.